Peptide Initiative

Peptides · Peptide comparison

Larazotide vs Thymosin Beta-4

Restore your intestinal barrier and protect against gluten damage

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeLarazotide0.5–0.5 mgThymosin Beta-42–5 mg
FrequencyLarazotideOnce dailyThymosin Beta-4Twice weekly
AdministrationLarazotideOral (capsule or tablet)Thymosin Beta-4Subcutaneous injection
Cycle lengthLarazotideOngoing/indefiniteThymosin Beta-48-12 weeks
Onset speedLarazotideModerate (1-2 weeks)Thymosin Beta-4Moderate (1-2 weeks)
Evidence levelLarazotideStrong human trials (Phase 3 or FDA approved)Thymosin Beta-4Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Intestinal Barrier Protection

Larazotide95%
Thymosin Beta-4No recorded rating

Celiac Disease Management

Larazotide85%
Thymosin Beta-4No recorded rating

Safety & Tolerability

Larazotide90%
Thymosin Beta-4No recorded rating

Wound Healing

LarazotideNo recorded rating
Thymosin Beta-495%

Inflammation Reduction

LarazotideNo recorded rating
Thymosin Beta-488%

Tissue Regeneration

LarazotideNo recorded rating
Thymosin Beta-492%

Technical data

Compound specifications

Larazotide

Molecular formula
C34H59N9O12
Molecular weight
785.9 g/mol
Half-life
Unknown - acts primarily as local intestinal barrier regulator rather than systemic drug
Bioavailability
Orally administered; acts locally on intestinal epithelium with minimal systemic absorption
CAS number
206899-25-6

Thymosin Beta-4

Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4

Protocols

Dosing compared

Larazotide

Oral

  • 0.5 mgThree times daily (before meals) · 12 weeks in trials; ongoing for symptom controlTrial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose [6]. Taken before meals as a local intestinal tight-junction regulator [1].

Thymosin Beta-4

Subcutaneous injection

  • 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.

Topical ophthalmic (eye drops)

  • 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].

Intravenous injection

  • 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].

Applications

Best suited for

Larazotide

Managing celiac disease symptoms despite strict gluten avoidance
Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
Reducing accidental gluten exposure damage
Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring digestive comfort and nutrient absorption
Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting intestinal healing and barrier function
Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Beta-4

Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety profile

Side effects

Larazotide

Common

  • Nausea
  • Abdominal Cramping
  • Fatigue

Uncommon

  • Transient Diarrhea

Serious

  • Allergic Reaction

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research status

Safety & evidence

Larazotide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved
Safety overview
Larazotide (AT-1001) is a synthetic tight-junction regulator. In Phase 2 celiac disease trials it reduced symptoms at the 0.5 mg dose, but a pooled analysis found no improvement in intestinal permeability versus placebo; safety was comparable to placebo [1][6]. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.

Contraindications

  • Known hypersensitivity to larazotide or any component
  • Severe gastrointestinal obstruction
  • Active untreated infections (may require monitoring)
  • Pregnancy and breastfeeding (limited safety data)

Thymosin Beta-4

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • Active systemic infections
  • Severe immunosuppression
  • Hypersensitivity to thymosin or any component
  • Pregnancy (insufficient safety data)

Decision guide

Which is right for you?

Larazotide

Choose Larazotide if…

  • Managing celiac disease symptoms despite strict gluten avoidance
  • Reducing accidental gluten exposure damage
  • Restoring digestive comfort and nutrient absorption
  • Supporting intestinal healing and barrier function

Thymosin Beta-4

Choose Thymosin Beta-4 if…

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation